Literature DB >> 8797967

Imaging in the staging of renal cell carcinoma.

R H Reznek1.   

Abstract

Imaging is extremely important in determining the type of surgery undertaken in patients with proven renal cell carcinoma. In this review, the strength and limitations of each of the relevant techniques are outlined, highlighting particularly the correlation between the imaging findings and the pathological staging. Over the past decade, CT has become the most widely used technique for staging renal cell carcinoma, partly due to the very high overall accuracy of up to 90% that has been achieved. MRI appears to have a similar overall accuracy to CT, whereas ultrasound is less accurate than CT or MRI in the overall staging of tumours. However, ultrasound is extremely accurate in identifying and localising the clinically important tumour extension into the intra-hepatic vena cava and right atrium and if local surgical practice requires only a knowledge of venous invasion, a technically adequate ultrasound examination may suffice. All techniques are unreliable in detecting early perinephric spread.

Entities:  

Mesh:

Year:  1996        PMID: 8797967     DOI: 10.1007/bf00181124

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  53 in total

1.  Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging.

Authors:  E K Outwater; E S Siegelman; P D Radecki; C W Piccoli; D G Mitchell
Journal:  AJR Am J Roentgenol       Date:  1995-09       Impact factor: 3.959

2.  Renal carcinoma: detection of venous extension with gradient-echo MR imaging.

Authors:  M A Roubidoux; N R Dunnick; H D Sostman; R A Leder
Journal:  Radiology       Date:  1992-01       Impact factor: 11.105

3.  The accuracy and limitations of ultrasound in the assessment of venous extension in renal carcinoma.

Authors:  J A Webb; A Murray; P R Bary; W F Hendry
Journal:  Br J Urol       Date:  1987-07

4.  Renal cell carcinoma: dynamic thin-section CT assessment of vascular invasion and tumor vascularity.

Authors:  R K Zeman; J J Cronan; A T Rosenfield; J H Lynch; M H Jaffe; L R Clark
Journal:  Radiology       Date:  1988-05       Impact factor: 11.105

5.  Stratification of risk factors in renal cell carcinoma.

Authors:  C Selli; W M Hinshaw; B H Woodard; D F Paulson
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

6.  Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases stage 1 and stage 2 patients.

Authors:  P V Targonski; W Frank; D Stuhldreher; P D Guinan
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

7.  The imaging evaluation of renal cell carcinoma: diagnosis and staging.

Authors:  B L McClennan; L A Deyoe
Journal:  Radiol Clin North Am       Date:  1994-01       Impact factor: 2.303

8.  Diagnosis and staging of renal cell carcinoma: a comparison of MR imaging and CT.

Authors:  A B Fein; J K Lee; D M Balfe; J P Heiken; D Ling; H S Glazer; B L McClennan
Journal:  AJR Am J Roentgenol       Date:  1987-04       Impact factor: 3.959

9.  Treatment of renal cell carcinoma by in situ partial nephrectomy and extracorporeal operation with autotransplantation.

Authors:  H Zincke; D E Engen; K M Henning; M W McDonald
Journal:  Mayo Clin Proc       Date:  1985-10       Impact factor: 7.616

10.  MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors.

Authors:  J H Bilbey; R F McLoughlin; P S Kurkjian; G E Wilkins; N H Chan; N Schmidt; J Singer
Journal:  AJR Am J Roentgenol       Date:  1995-03       Impact factor: 3.959

View more
  1 in total

1.  Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Authors:  Axel Bex; Astrid A M van der Veldt; Christian Blank; Alfons J M van den Eertwegh; Epie Boven; Simon Horenblas; John Haanen
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.